TY - JOUR
T1 - Humoral immunity against hepatitis B, tetanus, and diphtheria following chemotherapy for hematologic malignancies
T2 - a report and review of literature.
AU - Alavi, Samin
AU - Rashidi, Armin
AU - Arzanian, Mohammad Taghi
AU - Shamsian, Bibishahin
AU - Nourbakhsh, Kazem
PY - 2010/4
Y1 - 2010/4
N2 - Malignancy and its treatment are major causes of secondary immunodeficiency in childhood. The authors investigated the effects of chemotherapy on humoral immunity against hepatitis B, tetanus, and diphtheria in children with hematologic malignancies. The authors recruited 54 patients with hematologic malignancies after the completion of chemotherapy (group A), 25 patients with newly diagnosed hematologic malignancies before initiation of chemotherapy (group B), and 74 healthy controls (group C). All participants had been vaccinated against hepatitis B, tetanus, and diphtheria according to the Iranian national vaccination scheme. Patients in group A achieved protective levels of diphtheria and hepatitis B antibodies significantly less frequently than the other 2 groups and protective levels of tetanus antibody significantly less frequently than group C (P <.05). After controlling for age, the association observed for tetanus lost its significance, but chemotherapy was a significant and independent predictor of failure to achieve protective levels of antibodies against diphtheria (odds ratio [OR] = 7.7, P < .001) and hepatitis B (OR = 3.13, P = .008). These results indicate that chemotherapy has independent adverse effects on vaccine-induced antibody protection against diphtheria and hepatitis B.
AB - Malignancy and its treatment are major causes of secondary immunodeficiency in childhood. The authors investigated the effects of chemotherapy on humoral immunity against hepatitis B, tetanus, and diphtheria in children with hematologic malignancies. The authors recruited 54 patients with hematologic malignancies after the completion of chemotherapy (group A), 25 patients with newly diagnosed hematologic malignancies before initiation of chemotherapy (group B), and 74 healthy controls (group C). All participants had been vaccinated against hepatitis B, tetanus, and diphtheria according to the Iranian national vaccination scheme. Patients in group A achieved protective levels of diphtheria and hepatitis B antibodies significantly less frequently than the other 2 groups and protective levels of tetanus antibody significantly less frequently than group C (P <.05). After controlling for age, the association observed for tetanus lost its significance, but chemotherapy was a significant and independent predictor of failure to achieve protective levels of antibodies against diphtheria (odds ratio [OR] = 7.7, P < .001) and hepatitis B (OR = 3.13, P = .008). These results indicate that chemotherapy has independent adverse effects on vaccine-induced antibody protection against diphtheria and hepatitis B.
UR - http://www.scopus.com/inward/record.url?scp=77953929313&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953929313&partnerID=8YFLogxK
U2 - 10.3109/08880011003602141
DO - 10.3109/08880011003602141
M3 - Article
C2 - 20367262
AN - SCOPUS:77953929313
SN - 0888-0018
VL - 27
SP - 188
EP - 194
JO - Pediatric Hematology and Oncology
JF - Pediatric Hematology and Oncology
IS - 3
ER -
